An observational study in Hypertension, Pulmonary and Infant, Newborn, Diseases, sponsored by Assiut University. Not yet recruiting. Open to participants aged Up to 28 Days. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Assiut University · Observational
This prospective cohort study aims to identify the clinical, laboratory, and echocardiographic predictors of outcomes among neonates diagnosed with persistent pulmonary hypertension of the newborn at Assiut University Children Hospital.
Persistent pulmonary hypertension of the newborn (PPHN) is a serious condition characterized by failure of the normal postnatal decline in pulmonary vascular resistance, leading to severe hypoxemia. Outcomes vary widely, ranging from complete recovery to death.
This observational study will include term and preterm neonates admitted to the NICU with clinical and echocardiographic evidence of pulmonary hypertension. Clinical, laboratory, and echocardiographic parameters will be recorded to identify predictors of mortality and other adverse outcomes.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
This study's planned enrollment of 60 is below the median of 110 across 381 observational studies indexed under Hypertension, Pulmonary.
Browse Hypertension, Pulmonary studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Term and preterm neonates admitted to the Neonatal Intensive Care Unit of Assiut University Children Hospital with clinical and echocardiographic evidence of persistent pulmonary hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Term and preterm neonates with clinical and echocardiographic evidence of persistent pulmonary hypertension who will be followed for clinical, laboratory, and echocardiographic predictors of outcome.
In-hospital mortality
Proportion of neonates with persistent pulmonary hypertension who die before hospital discharge.
Time frame: Up to 30 days
Duration of mechanical ventilation
Total number of days of invasive mechanical ventilation.
Time frame: Up to 30 days
Duration of oxygen therapy
Total number of days requiring supplemental oxygen.
Time frame: Up to 30 days
Use of sildenafil
Proportion of neonates who receive sildenafil therapy.
Time frame: Up to 30 days
Use of inotropes
Proportion of neonates who receive inotropic support
Time frame: Up to 30 days
Duration of NICU stay
Length of stay in the neonatal intensive care unit in days.
Time frame: Up to 30 days
Time to echocardiographic resolution
Number of days from diagnosis until echocardiographic resolution of pulmonary hypertension.
Time frame: Up to 30 days
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.